Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

The purpose of this PQI in Action article is to demonstrate how NCODA’s Positive Quality Intervention (PQI) for enfortumab vedotin (Padcev®) plus pembrolizumab (Keytruda®) is applied in real-world oncology practice. It highlights how multidisciplinary teams at Huntsman Cancer Institute (Salt Lake City, UT) and University Hospitals (Cleveland, OH) use the PQI framework to guide patient selection, manage toxicities, and coordinate care through a Medically Integrated Pharmacy (MIP) model. By addressing both clinical management and financial navigation, the article shows how PQIs support providers in delivering safe, effective, and patient-centered treatment for advanced urothelial carcinoma.